1. Otezla (apremilast), manufactured by Summit, N.J.-based Celgene Corp., has been approved as a treatment for psoriatic arthritis in adults.
2. Xolair (omalizumab), co-developed and co-promoted by San Francisco-based Genentech and East Hanover, N.J.-based Novartis, has been approved to treat a chronic form of hives.
3. The FDA has approved Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) to be used as a preventative measure against potential pulmonary embolism-causing blood clots for patients who have undergone hip or knee replacement therapy.
4. The FDA has approved Myalept, metreleptin for injection, as a treatment option for patients with congenital generalized or acquired generalized lipodystrophy, a condition where patients have little to no fat tissue.
More Articles on Pharmaceuticals:
Pacira Joins NPSF Coalition
OxyContin Manufacturer Creates Tamper-Resistant Hydrocodone Drug
New Drugs Funneled $4B Into Exchange-Traded Funds in 2014
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
